Export

EN
FR
ATC codes: J05AP55
EMLc
Indication
Chronic hepatitis C ICD11 code: 1E91.1
INN
Sofosbuvir + velpatasvir
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Formulations
Oral > Solid > tablet: 200 mg + 50 mg (EMLc) ; 400 mg + 100 mg
Oral > Solid > granules: 150 mg + 37.5 mg in sachet (EMLc) ; 200 mg + 50 mg in sachet (EMLc)
EML status history
First added in 2017 (TRS 1006)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Changed in 2025 (TRS 1064)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations
Pangenotypic direct-acting antiviral combinations
Therapeutic alternatives limitations for EMLc
Pangenotypic direct-acting antiviral combinations
Patent information
Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of sofosbuvir + velpatasvir oral granules 150 mg + 37.5 mg and 200 mg + 50 mg to the EMLc.